+91 95694 49735 | info@potassiumclavulanate.com
WHO-GMP Certified

Our Journey of Growth & Excellence

2017 | Foundation Laid

Our journey began with the establishment of a state-of-the-art pharmaceutical manufacturing unit, marking the foundation of our manufacturing excellence.

2018 – 2019 | Manufacturing & Market Entry
  • Achieved ₹50 Cr business turnover
  • Integrated Beta-Lactam & Cephalosporin facility commissioned
  • Commercial operations initiated
  • WHO-GMP Certification received (2019)
2020 – 2021 | Resilience & Commitment
  • Crossed ₹100 Cr milestone
  • Uninterrupted supply during COVID-19
  • Operational resilience during global crisis
2022 – 2023 | Strategic Expansion
  • Business scaled to ₹150 Cr
  • Dedicated Beta-Lactam manufacturing plant established
2024 – 2025 | Global Entry
  • Turnover crossed ₹324 Cr
  • Export operations initiated
  • Regulatory approvals:
  • Cambodia – June 2025
  • Kenya – November 2025
  • Ghana – December 2025
2026 | Expanding Global Footprint
  • Manufacturing approvals secured for Vietnam & Uzbekistan
  • Regulatory approvals under process: Tanzania, Nigeria, Uganda